NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Relmada Therapeutics, Inc. (RLMD) Stock Analysis

Relmada Therapeutics, Inc. (RLMD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RLMD

$4.43

+$0.06 (+1.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RLMD with… →

RLMD Key Statistics

As of Sep 4, 2026
Trading
Open
$4.35
Previous Close
$4.37
Day's Range
4.32–4.44
52-Week Range
1.30–8.00
Volume
675.60K
Valuation
Market Cap
$472.55M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.92
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$57.39M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
106.67M
1-Year Return
+223.36%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
1.73M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RLMD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.28%
2025+828.85%
2024−87.44%
2023+18.62%
2022−84.51%
2021−29.75%
2020−17.77%
2019+747.83%
2018+53.33%
2017−31.19%
2016 (partial year)−31.01%

As of September 4, 2026.

RLMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$57.39M—
2024$0.00−$79.98M—
2023$0.00−$98.79M—
2022$0.00−$157.04M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$59.10M−$57.39M—
2024$0.00—−$83.89M−$79.98M—
2023$0.00—−$103.70M−$98.79M—
2022$0.00—−$161.25M−$157.04M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RLMD Valuation vs Biotechnology Median

Median of 656 stocks
MetricRLMDBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Relmada Therapeutics, Inc. (RLMD) is capitalised at $472.55M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 17 employees.

The 52-week range on file runs from $1.30 to $8.00. The most recent close on file for RLMD is $4.43, dated September 4, 2026. That is +$0.06 (+1.37%) against the previous close. The latest close sits 240.77% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $57.39M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.92.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Annualized volatility over the trailing 10 years is 113.55%. The trailing one-year price return is +223.36%. Across 10 years the annualized return works out at −3.61%.

Growth & Income

No dividend is on file for RLMD.

2026 is still running; the price is −8.28% year to date. Across the complete calendar years on file, 2025 returned +828.85% and 2024 returned −87.44%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Relmada Therapeutics, Inc. (RLMD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Relmada Therapeutics, Inc. RLMD $472.55M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Relmada Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Visit website →